For decades, Alzheimer's research has focused largely on managing symptoms rather than changing the course of the disease. A new generation of therapies is beginning to shift that conversation, with researchers now looking beyond clinical trials to see how these medicines perform in everyday healthcare.
According to data presented at the Alzheimer's Association International Conference (AAIC) 2026, alongside information from Eisai, Biogen and the U.S. Food and Drug Administration (FDA), fresh evidence suggests that Leqembi may help some people with early Alzheimer's maintain their abilities for longer outside the controlled setting of traditional studies, reports Medical News Today.
Why real-world data matters
Clinical trials are designed to answer whether a treatment works under carefully managed conditions. Real-world studies, however, examine how patients respond during routine medical care, offering a broader picture of long-term use and treatment decisions.
The latest findings come from the LEADER observational study, which followed 432 people with early Alzheimer's disease.
Also read: Here's the recommended number of ice creams to eat in a week
Participants had received Leqembi for an average of 17 months, allowing researchers to assess outcomes during standard clinical practice rather than in a tightly controlled research environment.
Encouraging early findings
The analysis found that roughly three-quarters of participants remained at the same stage of Alzheimer's during the observation period, while a smaller group was assessed as having improved to an earlier stage. Most patients also continued receiving the treatment, suggesting many were able to remain on therapy over time.
Researchers stress that these findings should be interpreted with caution. Because the study did not include an untreated comparison group and has not yet undergone peer review, it cannot establish that the observed outcomes were caused solely by the medication.
The bigger picture
Leqembi is designed to target amyloid protein deposits linked to Alzheimer's disease. While it is not a cure, researchers hope treatments that slow the progression of the condition could help patients preserve independence for longer before symptoms become more severe.
Also read: Your sex may determine which vegetables benefit your heart the most
The LEADER study adds another piece to the growing body of evidence surrounding disease-modifying therapies. Researchers plan to continue monitoring participants over the coming years to better understand the treatment's long-term effectiveness and safety in everyday clinical practice.
Also read: Does rinsing ground beef make it healthier? Here's the answer